Resources

Author(s) Contagion Editorial Team TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, offers some insights on the disease burden, and an overview of his company’s pipeline around developing a therapy for this STI. April is sexually transmitted infection (STI) Awareness Month, and with it brings [...]

World Health Day is a good moment to call attention to a silent emergency that’s putting the health of everyone on our planet at risk: Antimicrobial resistance (AMR) is quietly eroding the foundations of modern medicine. On a day when we talk about equity and [...]

February 10, 2026 — TAXIS Pharmaceuticals Australia Pty Ltd has named Angela Fonceca, PhD, an industry professional with extensive biopharma experience, to its Board of Directors. TAXIS Pharmaceuticals, a clinical-stage company focused on developing investigational therapies to combat multidrug-resistant bacterial infections and address antimicrobial resistance [...]

After decades of incremental antibiotic innovation, antimicrobial resistance (AMR) is outpacing our ability to respond, and 2026 may mark a breaking point. While US government prioritisation of AMR will likely remain low in 2026, the EU and Australia are ramping up incentives and R&D funding. [...]

A conversation with Ajit Parhi, Ph.D., chief scientific officer, TAXIS Pharmaceuticals Antimicrobial resistance (AMR) poses a grave threat to global public health and is estimated to cause around 10 million deaths each year by 2050if not addressed. While U.S. government prioritization of AMR is likely [...]

By Gregory G. Mario, MBA, president and CEO, TAXIS Pharmaceuticals The ground beneath our feet is shifting. The foundational promise of modern medicine — that bacterial infections are a solvable problem – is being severely tested by an accelerating crisis: antimicrobial resistance (AMR). 2025 brought [...]

US infections caused by NDM-producing carbapenem-resistant Enterobacterales (NDM-CRE) increased by more than 460% from 2019 to 2023, according to a Centers for Disease Control and Prevention (CDC) analysis published in Annals of Internal Medicine. CDC cautions that this surge could raise overall carbapenem-resistant Enterobacterales (CRE) infections [...]

September 25, 2025 — TAXIS Pharmaceuticals today issued a statement in response to a new report from the Centers for Disease Control and Prevention (CDC), published in the Annals of Internal Medicine on September 23. The CDC report highlights a dramatic increase in infections caused [...]

Podcast Interview: The Bio Report: Overcoming Antibiotic Resistance Listen to the podcast here. Antimicrobial resistance is projected to kill up to 10 million people a year by 2050. One particular area of concern is drug-resistant gonorrhea, where existing therapies are being exhausted. Taxis Pharmaceuticals is [...]